Do analysts prefer TAOX or FTLF?

FitLife Brands has a consensus price target of $21.50, suggesting a potential upside of 86.96%. Given FitLife Brands' stronger consensus rating and higher possible upside, analysts plainly believe FitLife Brands is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 FitLife Brands 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Do analysts prefer TAOX or AARD?

Aardvark Therapeutics has a consensus price target of $19.70, suggesting a potential upside of 245.61%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aardvark Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aardvark Therapeutics 2 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.46

Is TAOX or AARD more profitable?

Aardvark Therapeutics' return on equity of -61.71% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix N/A -163.40% -133.47% Aardvark Therapeutics N/A -61.71% -56.29%

Does the media refer more to TAOX or AARD?

In the previous week, Synaptogenix and Synaptogenix both had 1 articles in the media. Aardvark Therapeutics' average media sentiment score of 0.59 beat Synaptogenix's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synaptogenix 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aardvark Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TAOX or ETHZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Flag Ship Acquisition 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is TAOX or ETHZ more profitable?

Synaptogenix's return on equity of -163.40% beat Flag Ship Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix N/A -163.40% -133.47% Flag Ship Acquisition N/A -185.71% -83.12%

Do analysts prefer KLRS or TAOX?

Kalaris Therapeutics presently has a consensus price target of $15.60, suggesting a potential upside of 228.42%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Kalaris Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kalaris Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is KLRS or TAOX more profitable?

Kalaris Therapeutics' return on equity of -72.78% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Kalaris Therapeutics N/A -72.78% -43.49% Synaptogenix N/A -163.40% -133.47%

Do analysts rate TAOX or AADI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Synaptogenix (TAOX) Competitors

$3.66 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$3.74 +0.08 (+2.19%)

As of 07/2/2026 07:56 PM Eastern

Compare

TAOX vs. FTLF, AARD, ETHZ, KLRS, and AADI

Should you buy Synaptogenix stock or one of its competitors? MarketBeat compares Synaptogenix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Synaptogenix include FitLife Brands (FTLF), Aardvark Therapeutics (AARD), Flag Ship Acquisition (ETHZ), Kalaris Therapeutics (KLRS), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry.

How does Synaptogenix compare to FitLife Brands?

Synaptogenix (NASDAQ:TAOX) and FitLife Brands (NASDAQ:FTLF) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

FitLife Brands has a net margin of 6.64% compared to Synaptogenix's net margin of 0.00%. FitLife Brands' return on equity of 18.31% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
FitLife Brands	6.64%	18.31%	8.21%

In the previous week, Synaptogenix had 1 more articles in the media than FitLife Brands. MarketBeat recorded 1 mentions for Synaptogenix and 0 mentions for FitLife Brands. Synaptogenix's average media sentiment score of 0.00 equaled FitLife Brands'average media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
FitLife Brands	Neutral

FitLife Brands has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than FitLife Brands, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	91.13	-$28.74M	-$13.28	N/A
FitLife Brands	$81.46M	1.33	$6.33M	$0.60	19.17

FitLife Brands has a consensus price target of $21.50, suggesting a potential upside of 86.96%. Given FitLife Brands' stronger consensus rating and higher possible upside, analysts plainly believe FitLife Brands is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
FitLife Brands	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 2.3% of FitLife Brands shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 61.7% of FitLife Brands shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Synaptogenix has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, FitLife Brands has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market.

Summary

FitLife Brands beats Synaptogenix on 11 of the 15 factors compared between the two stocks.

How does Synaptogenix compare to Aardvark Therapeutics?

Synaptogenix (NASDAQ:TAOX) and Aardvark Therapeutics (NASDAQ:AARD) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Synaptogenix has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Aardvark Therapeutics has a beta of 3.93, indicating that its share price is 293% more volatile than the broader market.

Synaptogenix has higher revenue and earnings than Aardvark Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	91.13	-$28.74M	-$13.28	N/A
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A

In the previous week, Synaptogenix and Synaptogenix both had 1 articles in the media. Aardvark Therapeutics' average media sentiment score of 0.59 beat Synaptogenix's score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synaptogenix	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aardvark Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aardvark Therapeutics' return on equity of -61.71% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
Aardvark Therapeutics	N/A	-61.71%	-56.29%

10.3% of Synaptogenix shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Aardvark Therapeutics has a consensus price target of $19.70, suggesting a potential upside of 245.61%. Given Aardvark Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aardvark Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.46

Summary

Aardvark Therapeutics beats Synaptogenix on 9 of the 14 factors compared between the two stocks.

How does Synaptogenix compare to Flag Ship Acquisition?

Synaptogenix (NASDAQ:TAOX) and Flag Ship Acquisition (NASDAQ:ETHZ) are both small-cap manufacturing companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Synaptogenix had 1 more articles in the media than Flag Ship Acquisition. MarketBeat recorded 1 mentions for Synaptogenix and 0 mentions for Flag Ship Acquisition. Synaptogenix's average media sentiment score of 0.00 equaled Flag Ship Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
Flag Ship Acquisition	Neutral

Synaptogenix has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, Flag Ship Acquisition has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market.

Synaptogenix's return on equity of -163.40% beat Flag Ship Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
Flag Ship Acquisition	N/A	-185.71%	-83.12%

Flag Ship Acquisition has higher revenue and earnings than Synaptogenix. Synaptogenix is trading at a lower price-to-earnings ratio than Flag Ship Acquisition, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	91.13	-$28.74M	-$13.28	N/A
Flag Ship Acquisition	$4.11M	27.85	-$6.17M	-$159.65	N/A

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 4.1% of Flag Ship Acquisition shares are held by institutional investors. 2.7% of Synaptogenix shares are held by company insiders. Comparatively, 15.1% of Flag Ship Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Flag Ship Acquisition	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Synaptogenix beats Flag Ship Acquisition on 6 of the 11 factors compared between the two stocks.

How does Synaptogenix compare to Kalaris Therapeutics?

Kalaris Therapeutics (NASDAQ:KLRS) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.

Synaptogenix has higher revenue and earnings than Kalaris Therapeutics. Kalaris Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kalaris Therapeutics	N/A	N/A	-$43.44M	-$2.15	N/A
Synaptogenix	$300K	91.13	-$28.74M	-$13.28	N/A

Kalaris Therapeutics presently has a consensus price target of $15.60, suggesting a potential upside of 228.42%. Given Kalaris Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Kalaris Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kalaris Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Synaptogenix had 1 more articles in the media than Kalaris Therapeutics. MarketBeat recorded 1 mentions for Synaptogenix and 0 mentions for Kalaris Therapeutics. Kalaris Therapeutics' average media sentiment score of 0.00 equaled Synaptogenix'saverage media sentiment score.

Company	Overall Sentiment
Kalaris Therapeutics	Neutral
Synaptogenix	Neutral

Kalaris Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market.

Kalaris Therapeutics' return on equity of -72.78% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kalaris Therapeutics	N/A	-72.78%	-43.49%
Synaptogenix	N/A	-163.40%	-133.47%

66.1% of Kalaris Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 68.1% of Kalaris Therapeutics shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Kalaris Therapeutics beats Synaptogenix on 9 of the 14 factors compared between the two stocks.

How does Synaptogenix compare to Aadi Bioscience?

Synaptogenix (NASDAQ:TAOX) and Aadi Bioscience (NASDAQ:AADI) are both small-cap pharmaceutical preparations industry companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

In the previous week, Synaptogenix had 1 more articles in the media than Aadi Bioscience. MarketBeat recorded 1 mentions for Synaptogenix and 0 mentions for Aadi Bioscience. Synaptogenix's average media sentiment score of 0.00 equaled Aadi Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Synaptogenix	Neutral
Aadi Bioscience	Neutral

10.3% of Synaptogenix shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Synaptogenix has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	91.13	-$28.74M	-$13.28	N/A
Aadi Bioscience	$25.07M	4.13	-$65.76M	-$2.35	N/A

Synaptogenix has a beta of 1.42, suggesting that its share price is 42% more volatile than the broader market. Comparatively, Aadi Bioscience has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Synaptogenix has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Aadi Bioscience's return on equity of -71.87% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Summary

Synaptogenix beats Aadi Bioscience on 7 of the 13 factors compared between the two stocks.

Get Synaptogenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAOX vs. The Competition

Export

Metric	Synaptogenix	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$27.35M	$791.45M	$5.20B	$12.48B
Dividend Yield	N/A	4.84%	16.11%	6.52%
P/E Ratio	-0.28	1.66	23.91	24.70
Price / Sales	91.13	127.11	216.83	99.42
Price / Cash	N/A	20.06	35.06	57.09
Price / Book	1.29	8.17	13.25	6.46
Net Income	-$28.74M	-$3.71M	$113.80M	$337.01M
7 Day Performance	2.23%	2.59%	0.93%	1.69%
1 Month Performance	-3.94%	4.41%	1.08%	3.81%
1 Year Performance	N/A	49.43%	10.03%	23.90%

Synaptogenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAOX Synaptogenix	0.0598 of 5 stars	$3.66 flat	N/A	N/A	$27.35M	$300K	N/A	4	News Coverage
FTLF FitLife Brands	4.5314 of 5 stars	$11.44 +3.3%	$21.50 +87.9%	-18.4%	$107.49M	$81.46M	18.95	20	Gap Down
AARD Aardvark Therapeutics	3.9205 of 5 stars	$4.90 +2.3%	$19.70 +302.2%	-59.1%	$107.46M	N/A	N/A	18	Analyst Upgrade Gap Down
ETHZ Flag Ship Acquisition	N/A	$5.58 +7.3%	N/A	N/A	$106.09M	$4.11M	N/A	7	Gap Up
KLRS Kalaris Therapeutics	3.5397 of 5 stars	$4.36 +0.9%	$15.60 +257.8%	+90.0%	$103.72M	N/A	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TAOX) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synaptogenix (TAOX) Competitors

TAOX vs. FTLF, AARD, ETHZ, KLRS, and AADI

How does Synaptogenix compare to FitLife Brands?

Summary

How does Synaptogenix compare to Aardvark Therapeutics?

Summary

How does Synaptogenix compare to Flag Ship Acquisition?

Summary

How does Synaptogenix compare to Kalaris Therapeutics?

Summary

How does Synaptogenix compare to Aadi Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synaptogenix (TAOX) Competitors

TAOX vs. FTLF, AARD, ETHZ, KLRS, and AADI

How does Synaptogenix compare to FitLife Brands?

Is TAOX or FTLF more profitable?

Does the media prefer TAOX or FTLF?

Which has preferable earnings and valuation, TAOX or FTLF?

Do analysts prefer TAOX or FTLF?

Do insiders and institutionals hold more shares of TAOX or FTLF?

Which has more volatility and risk, TAOX or FTLF?

Summary

How does Synaptogenix compare to Aardvark Therapeutics?

Which has more volatility and risk, TAOX or AARD?

Which has stronger valuation & earnings, TAOX or AARD?

Does the media refer more to TAOX or AARD?

Is TAOX or AARD more profitable?

Do institutionals & insiders hold more shares of TAOX or AARD?

Do analysts prefer TAOX or AARD?

Summary

How does Synaptogenix compare to Flag Ship Acquisition?

Does the media refer more to TAOX or ETHZ?

Which has more risk & volatility, TAOX or ETHZ?

Is TAOX or ETHZ more profitable?

Which has higher earnings & valuation, TAOX or ETHZ?

Do institutionals & insiders hold more shares of TAOX or ETHZ?

Do analysts prefer TAOX or ETHZ?

Summary

How does Synaptogenix compare to Kalaris Therapeutics?

Which has preferable earnings and valuation, KLRS or TAOX?

Do analysts prefer KLRS or TAOX?

Does the media favor KLRS or TAOX?

Which has more volatility and risk, KLRS or TAOX?

Is KLRS or TAOX more profitable?

Do institutionals & insiders hold more shares of KLRS or TAOX?

Summary

How does Synaptogenix compare to Aadi Bioscience?

Does the media favor TAOX or AADI?

Do institutionals and insiders believe in TAOX or AADI?

Which has better earnings and valuation, TAOX or AADI?

Which has more volatility & risk, TAOX or AADI?

Do analysts rate TAOX or AADI?

Is TAOX or AADI more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools